Germany
Germany Oncology Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Germany · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany (this report) at $452.7 Mn.
Italy at 14.8% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$973.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $398.5 Mn | — | — |
| 2025 (base) | $452.7 Mn | +$54.2 Mn | — |
| 2026 (forecast) | $514.3 Mn | +$61.6 Mn | +13.6% |
| 2027 (forecast) | $584.2 Mn | +$69.9 Mn | +29% |
| 2028 (forecast) | $663.7 Mn | +$79.5 Mn | +46.6% |
| 2029 (forecast) | $753.9 Mn | +$90.3 Mn | +66.5% |
| 2030 (forecast) | $856.5 Mn | +$102.5 Mn | +89.2% |
| 2031 (forecast) | $972.9 Mn | +$116.5 Mn | +114.9% |
| 2032 (forecast) | $1.11 Bn | +$132.3 Mn | +144.1% |
| 2033 (forecast) | $1.26 Bn | +$150.3 Mn | +177.3% |
| 2034 (forecast) | $1.43 Bn | +$170.8 Mn | +215.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$4.41 Bn
China
$927.5 Mn
Canada
$887.7 Mn
Japan
$636.5 Mn
Germany (this report)
$452.7 Mn
France
$371.6 Mn
Brazil
$336.0 Mn
Italy
$302.5 Mn
UK
$282.2 Mn
Ecuador
$236.9 Mn
Spain
$202.5 Mn
India
$212.2 Mn
Saudi Arabia
$205.4 Mn
Mexico
$160.2 Mn
Australia
$148.3 Mn
New Zealand
$138.8 Mn
Russia
$110.4 Mn
South Africa
$79.0 Mn
UAE
$51.8 Mn
Egypt
$35.2 Mn
Philippines
$22.8 Mn
Hong Kong
$22.1 Mn
Malaysia
$18.0 Mn
Thailand
$16.5 Mn
Singapore
$12.8 Mn
Kenya
$7.4 Mn
Oncology biosimilars are lower-cost versions of cancer biologic drugs such as trastuzumab and bevacizumab.
Key segments of the oncology Biosimilars market include molecule (Trastuzumab, Bevacizumab and Rituximab) and cancer (Breast, Colorectal and Lymphoma).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the oncology Biosimilars market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the oncology Biosimilars market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the oncology Biosimilars market, especially in low- and middle-income countries.
The oncology Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oncology Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.
What doctors and scientists are doing in Oncology Biosimilars right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Germany · 2 shared keywords
Germany · 2 shared keywords
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany · 1 shared keyword
Germany · 1 shared keyword
Digital Health · Germany
Medical Devices · Germany
Healthcare Services · Germany
Healthcare Services · Germany
Healthcare Services · Germany
Healthcare Services · Germany
